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Abstract
Background—Recently, epidemiological and clinical data have revealed important changes with
regard to clinical adenovirus infection, including alterations in antigenic presentation, geographical
distribution, and virulence of the virus.
Methods—In an effort to better understand the epidemiology of clinical adenovirus infection in the
United States, we adopted a new molecular adenovirus typing technique to study clinical adenovirus
isolates collected from 22 medical facilities over a 25-month period during 2004-2006. A hexon gene
sequence typing method was used to characterize 2237 clinical adenovirus-positive specimens,
comparing their sequences with those of the 51 currently recognized prototype human adenovirus
strains. In a blinded comparison, this method performed well and was much faster than the classic
serologic typing method.
Results—Among civilians, the most prevalent adenovirus types were types 3 (prevalence, 34.6%),
2 (24.3%), 1 (17.7%), and 5 (5.3%). Among military trainees, the most prevalent types were types
4 (prevalence, 92.8%), 3 (2.6%), and 21 (2.4%).
Conclusions—For both populations, we observed a statistically significant increasing trend of
adenovirus type 21 detection over time. Among adenovirus isolates recovered from specimens from
civilians, 50% were associated with hospitalization, 19.6% with a chronic disease condition, 11%
with a bone marrow or solid organ transplantation, 7.4% with intensive care unit stay, and 4.2% with
a cancer diagnosis. Multivariable risk factor modeling for adenovirus disease severity found that age
<7 years (odds ratio [OR], 3.2; 95% confidence interval [CI], 1.4-7.4), chronic disease (OR, 3.6; 95%
CI, 2.6-5.1), recent transplantation (OR, 2.7; 95% CI, 1.3-5.2), and adenovirus type 5 (OR, 2.7; 95%
CI, 1.5-4.7) or type 21 infection (OR, 7.6; 95% CI, 2.6-22.3) increased the risk of severe disease.
More than 35 years ago, population-based studies of viral respiratory illnesses among US
families were conducted in Ohio [1], Kansas [2], Louisiana [3], New York [4], and Washington
[5]. As a result of these investigations, scientists concluded that adenovirus infection was quite
common among children. Approximately 50% of infections were asymptomatic, and
symptomatic infections were typically mild and resolved without sequelae. In contrast, military
populations experienced severe epidemics of acute respiratory disease, including pneumonia
and encephalitis, especially involving adenovirus types 4, 7, and 21. For example, in 1958,
adenoviral infection was reported to have caused hospitalization of an estimated 10% of
military recruits [6] and to be the etiology of most respiratory disease during winter months.
Subsequently, vaccines for adenovirus types 4 and 7 were developed and effectively used
among US military trainees from the 1970s until the late 1990s [7,8]. Thus, until recently,
adenovirus infection was considered to have little consequence, except for causing morbidity
among military trainees.
However, much has changed since these early epidemiological studies were conducted. In
contrast to the modest number of adenovirus types recognized 35 years ago, 51 unique
serotypes are now recognized. Different serotypes have been found to have different tissue
tropisms that correlate with different clinical manifestations of infection. Limited
epidemiological investigations have revealed that, among some specific serotypes, multiple
genetic variants exist that often have quite different geographical distributions and associated
virulence [9-11]. In addition, largely because of molecular diagnostics, adenovirus infection
has been associated with a number of acute and chronic diseases, including chronic airway
obstruction [12] and pulmonary dysplasia [13], myocarditis and dilated cardiomyopathy [14],
mononucleosis-like syndromes [15], intussusception [16], sudden infant perinatal death [17],
and obesity [18,19]. Among some population groups, adenoviral infection is common and,
often, severe. For example, the incidence of adenoviral disease among bone marrow transplant
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recipients varies from 3% to 20% [20], and mortality can exceed 50% [21]. Similarly, multiple
recent outbreaks of adenoviral infection in the United States have frequently occurred among
institutionalized children and in medical settings, resulting in significant morbidity and
mortality among patients and medical staff [22]. In vitro studies suggest that specific
adenovirus types are more likely to respond to certain antiviral therapies [23]. Finally, since
the military lost its manufacturer of adenovirus types 4 and 7 vaccines in the late 1990s,
numerous outbreaks of adenovirus infection have occurred among military trainees, resulting
in great morbidity [24,25]. Subsequently, the US Department of Defense identified a new
vaccine manufacturer, and restoration of adenovirus types 4 and 7 vaccines is projected for
2008 [25]. It seems prudent to investigate whether previously very effective and safe vaccines
may also benefit some nonmilitary populations. Therefore, an updated look at the epidemiology
of human adenovirus infection is warranted. In this report, we present 25 months of viral and
patient epidemiological data on clinical adenovirus infection detected through a nationwide
network of 22 US military and civilian medical facilities. We used a recently described
molecular adenovirus typing technique to characterize the strains of adenovirus [26].
MATERIALS AND METHODS
Population
From July 2004 through September 2006, specimens that were positive for adenovirus by rapid
diagnostic test, PCR, or culture were collected from 22 US medical facilities. Of these facilities,
8 were military sites located in California, Georgia, Illinois, Missouri, New Jersey, South
Carolina (2 sites), and Texas, and 14 were civilian laboratories located in Arizona, Colorado,
Connecticut, Indiana, Florida, North Carolina, New York (2 sites), Missouri (2 sites),
Tennessee, Texas, Washington, and Wisconsin. Samples were collected as part of routine
testing, labeled with unique study identifiers, and sent to the University of Iowa Center for
Emerging Infectious Diseases (Iowa City) for genetic typing. This study was approved by the
multiple institutional review boards representing the participating laboratories.
As part of routine viral respiratory pathogen surveillance [25], the military laboratories first
submitted specimens to the Navy Respiratory Disease Laboratory in San Diego, California.
Each month, after viral identification work, the Navy laboratory shared a sample set of ∼30
specimens with the Center for Emerging Infectious Diseases. This sample set represented
specimens that were positive for adenovirus from each of the 8 sites, distributed over time. For
adenovirus-positive specimens, the Navy laboratory provided the specimen collection date and
the age, sex, and training site of the patient from whom the specimen was obtained.
Civilian laboratories were asked to submit all adenovirus-positive specimens. Limited
demographic and clinical data were obtained from each civilian specimen, including the
laboratory collection site (city and state), collection date, specimen source (e.g., nasal,
pharyngeal or blood), and specimen type (e.g., culture, direct fluorescent antibody, or PCR),
as well as patient birth date and sex, whether the patient was hospitalized when the specimen
was collected, and whether the patient had undergone transplantation during the 6 months prior
to specimen collection. Because of their risk for severe disease, additional information (race
and ethnicity, clinical presentation, hospitalization care, disposition, cancer status, and chronic
disease status) was obtained from patients with adenovirus infection who were aged <7 years
or who had undergone transplantation within 6 months before the positive adenovirus result.
The cutoff value of <7 years of age was based on a recent investigation of an outbreak of
adenovirus type 7d2 infection (among 93 patients, with a 33% attack rate and 8 deaths), in
which children aged <7 years were found to be at increased risk for illness [22].
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DNA extraction, PCR, and sequencing
After an initial study, we found that most adenovirus-positive specimens yielded PCR
amplification products without requiring additional culture enrichment. Viral DNA was
extracted from 200 μL of the original adenovirus-positive specimen in a final elution volume
of ∼200 μL using the QIAamp DNA Blood Mini Kit (Qiagen). An initial volume of 5 μL of
eluted sample was amplified using a PCR procedure that targeted hypervariable regions 1-6 of
the hexon gene [26]. M13 universal priming tails (forward, 5′-TGT AAA ACG ACG GCC
AGT-3′; and reverse, 5′-CAG GAA ACA GCT ATG ACC-3′) were added to the previously
described primers to facilitate sequencing. Expected amplicons from this reaction ranged from
764 to 896 bp in length. These amplicons were then sequenced on a 3730 xl DNA Analyser
(Applied BioSystems). The forward and reverse sequences were combined using BioEdit (Ibis
Therapeutics) and were compared with the similar sequences of 51 well-characterized
prototype viruses and other well-characterized genotypes from our collections and from
GenBank. Specimens that yielded identity scores ≥90%, compared with both our internal
sequence database and that of GenBank, were considered to be good genotype matches.
Culture
When PCR amplification failed, the original specimen was inoculated into A549 cells (ATCC)
and incubated at 37°C for 4-7 days or until a cytopathic effect was observed. If, after 7 days,
no cytopathic effect was detected, cells were cultured again. After cytopathic effect was
confirmed, the positive cell culture specimen was characterized by PCR and sequencing.
Validation
A systematic sample of 101 adenovirus-positive specimens containing numerous genotypes
was shared with the Viral and Rickettsial Disease Laboratory of the California Department of
Health Services (Richmond) for blinded validation using classic serotyping techniques. This
laboratory shared 3 of these specimens with the Navy Respiratory Disease Laboratory for
further study using a PCR adenovirus typing algorithm [27].
Statistical analyses
Questionnaire and laboratory data were linked by the unique specimen number. In instances
in which several adenovirus-positive specimens were obtained from the same patient and
clinical event, the linkage of these specimens was indicated by the civilian laboratories using
study forms. During studies of clinical outcomes, only the first adenovirus-positive specimen
was considered in studies of clinical events. The χ2 test and Fisher’s exact test were used to
examine potential risk factor associations. The exact Cochran-Armitage test for trend was used
to examine adenovirus genotype prevalence across years. Logistic regression modeling was
used to examine potential risk factors for outcomes, such as pneumonia. The proportional odds
model was used to examine risk factors for severe adenovirus infection, considering the
outcomes of hospitalization, intensive care unit stay, and death in a mutually exclusive, ordinal
severity scale based on data on the first adenovirus-positive specimen for the clinical event.
These 3 final multivariable models were derived using a saturated model and manual
backwards elimination. Analyses were performed using SAS, version 9.1 (SAS Institute).
RESULTS
Validation
In the blinded validation study, 98 (97%) of the 101 adenovirus-positive specimens were
typeable using type-specific neutralization. Serotyping agreed with genotyping for all 98
specimens. The remaining 3 specimens of unknown types were studied using a novel and quite
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different PCR typing algorithm [27], and the blinded results of this algorithm were in agreement
with University of Iowa genotyping methods.
Genotyping by PCR and sequencing
During the study period, 2237 adenovirus-positive specimens were received (1653 specimens
from civilians and 584 from military trainees). All of the specimens from military trainees
resulted from culture. Specimen type information was available for 1170 specimens from
civilians; 84.9% of specimens were isolated by culture, 7.9% by direct fluorescent antibody,
and 7.2% by PCR assays. Ninety-eight percent of the 2237 adenovirus-positive specimens were
successfully typed by PCR and sequencing. Of the 47 initially nontypeable specimens, 27
(57.4%) were eventually typed after statistical analysis had been concluded, 4 (8.5%) were not
confirmed to be positive for adenovirus by PCR, and 16 (34.0%) were confirmed to be positive
for adenovirus by PCR, but the sequence data were inconclusive. The samples that were not
confirmed to be positive for adenovirus by PCR may represent false-positive specimens or
specimens with low viral titer that did not yield adenovirus by culture. The samples confirmed
to be positive for adenovirus by PCR that had inconclusive sequence data may represent dual
adenovirus infections or infection with novel viruses. We are further analyzing these
specimens.
The 582 successfully typed specimens from military trainees were comprised primarily of
adenovirus hexon sequence genotypes (HSgenotypes) 4 (92.8% of specimens), 3 (2.6%), and
21 (2.4%) (table 1). The age and sex distribution of patients with adenovirus infection were
consistent with the demographic characteristics of military training populations. During the
study period, there was a statistically significant increasing trend in the prevalence of
adenovirus type 21 isolates and a decreasing trend in the prevalence of type 4 isolates. These
data represent only a small subset and limited time distribution of adenovirus isolates found
in specimens from military trainees. Detailed analyses of a more comprehensive sample set
are the subject of a separate report (K.L.R., unpublished data).
Specimens from civilians yielded a more diverse distribution of adenovirus HSgenotypes, with
23 different types detected (table 2). Among the 1608 adenovirus-positive specimens
successfully typed, 76.8% were from children aged <7 years, 59% were from male patients,
71.0% were from upper respiratory tract sites, and 49.6% were associated with hospitalization.
The most prevalent adenovirus HSgenotypes were types 3 (34.6% of specimens), 2 (24.3%),
1 (17.7%), and 5 (5.3%). The distribution of HSgenotypes differed by age group (with types
1 and 2 being more prevalent among patients aged <7 years) and by specimen source (with
types 1, 3, and 2 being most prevalent among blood, upper respiratory tract, and gastrointestinal
tract specimens, respectively).
For the 1059 unique clinical events experienced by patients with adenovirus infection who
were aged <7 years or who had undergone transplantation within 6 months prior to specimen
collection, more clinical information was obtained. Of these patients, 95.3% were aged <7
years, 58.9% were male, 11.0% reported to have recently received a transplant, and 4.2% had
received a diagnosis of cancer (table 3). Sixty-seven (57.8%) of the 116 transplant recipients
had received a bone marrow transplant (data not shown). Thirty-four (58.8%) of the 45 patients
with cancer had cancer of lymphatic and hematopoietic origin (data not shown). Four hundred
fifty (42.5%) of the 1059 patients with adenovirus infection presented with upper respiratory
tract infection. Two hundred fifty-five patients (24.1%) were hospitalized for ≥4 days (median
duration of hospitalization, 3 days). Two hundred eight patients (19.6%) had a chronic disease,
and 78 (7.4%) had stayed in an intensive care unit. Because certain populations were thought
to be at risk of severe adenovirus infection, the characteristics of patients aged <7 years were
stratified by immune status and compared with the characteristics of immunocompromised
patients aged ≥7 years (table 4). In general, nonimmunocompromised children aged <7 years
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experienced more adenovirus type 3 infections and more upper respiratory tract infections than
did immunocompromised children aged <7 years; however, the nonimmunocompromised
children had less severe disease and were less likely to have numerous adenovirus isolates per
clinical event.
A number of laboratories submitted multiple adenovirus-positive specimens for a single
clinical event. Most of these specimens were of the same genotype; however, 20 unique clinical
events were found to be associated with laboratory evidence of infection with ≥2 adenovirus
HSgenotypes (table 5). Most of these infections involving multiple adenovirus HSgenotypes
occurred in immunocompromised patients who were aged <7 years.
The multivariable risk factor modeling (table 6) for adenovirus disease severity (death or
intensive care unit stay vs. hospitalization vs. other disease) revealed some interesting findings.
As expected, patients aged <7 years (OR, 3.2; 95% CI, 1.4-7.4), patients with chronic disease
(OR, 3.6; 95% CI, 2.6-5.1), and patients who had recently undergone transplantation (OR, 2.7;
95% CI, 1.3-5.2) had an increased risk of severe disease. However, unexpectedly, patients
infected with adenovirus type 5 (OR, 2.7; 95% CI, 1.5-4.7) or 21 (OR, 7.6; 95% CI, 2.6-22.3)
also had a higher risk of developing severe adenovirus disease. Similar multivariable modeling
was performed for the outcome of pneumonia, but no specific adenovirus types were associated
with this condition (data not shown).
DISCUSSION
Sequencing of hypervariable regions 1-6 of the adenovirus hexon gene [26] appears to correlate
well with serological and other molecular methods for typing human adenovirus and, unlike
serological methods that can take weeks to perform, can generally be completed within 2 days.
It is likely that PCR and sequencing will replace older, classic adenovirus serotyping methods,
because PCR and sequencing have the potential to provide rapid results to clinicians and public
health officials evaluating and treating specific patients and responding to outbreaks of
adenovirus infection. Conversion from classic serotyping to genotyping of adenovirus is not
unlike similar recent shifts for the study of group A streptococci [28] and enterovirus [29].
Typing results yielded some interesting observations. The high prevalence of infection with
adenovirus type 4 HSgenotypes among patients in the military is consistent with a recent report
[25]. However, the increased prevalence of adenovirus type 21 infection among both military
and civilian patients was unexpected (tables 1 and 2). Because prevalence figures for
adenovirus infection have been known to fluctuate over time, these changes were not
significantly alarming. However, adenovirus type 21 infection has caused sporadic outbreaks
among military [30-32] and civilian populations [33,34], and changes in prevalence must be
evaluated as possible indicators of the emergence of a novel strain. Because of such outbreaks,
adenovirus type 21 vaccine development efforts were attempted [30,35,36] but never finalized,
because morbidity associated with adenovirus 21 infection has remained low [7]. The high
prevalence of hospitalization among the patients with adenovirus infection (table 2) was
surprising. This may reflect the desire of clinicians to more frequently determine the etiology
of an infection in patients sick enough to merit hospitalization. However, this high prevalence
of hospitalization, the significant number of patients with adenovirus infection who require
hospitalization in an intensive care unit, and the relatively long duration of hospitalization that
is experienced for patients with adenovirus infection reflect the impact on morbidity that
adenovirus infection has in US medical care facilities today.
Before this surveillance effort was initiated, adenovirus type 7 infection was predicted to have
a strong association with severe morbidity. Worldwide, various adenovirus type 7 genotypes
have emerged to cause epidemics and severe disease [9,37-47]. However, thus far in this
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surveillance, adenovirus type 7 infection has not been implicated to have a strong association
with severe morbidity. This could be because of a stabilization of circulating adenovirus type
7 genotypes in the United States—as was recently apparent in Iowa for the strain adenovirus
type 7d2 [10]—with subsequent increases in herd immunity and reductions in adenovirus type
7 infections. Previous reports have noted that outbreaks of adenovirus type 7 infection seem
to be sporadic [40,48] and may be the result of the emergence of new type 7 subtypes [9,40,
48].
The association of adenovirus types 5 and 21 with severe disease (table 6) was unexpected.
Although adenovirus types 5 and 21 are associated with novel strains [49], epidemics [33,34,
50,51], severe disease [52], and death [53], these observations have been relatively rare. Our
data revealed that, of the 13 patients with adenovirus infection who died, 1 had been infected
with adenovirus type 5 (1.7% of the patients infected with type 5), and 2 had been infected
with type 21 (14.3% of the patients infected with type 21). Although the data supporting these
findings are rather sparse, the observations merit continued study.
Additionally interesting was the relatively high number of patients detected as having
infections with multiple adenovirus isolates over time, with multiple adenovirus types being
identified during a single clinical event (tables 3, 4 and 5). Recent reports regarding repeat
adenovirus detections in immunocompromised patients [54] and multiple strains causing
concomitant infection in US military trainees [55] seem to reinforce our observation,
illustrating the complexities of evaluating adenovirus infection. Molecular typing strategies
are thus useful in evaluating adenovirus infection epidemics and individual patients. For
instance, a transplant clinician might use molecular typing to discern whether a patient is
experiencing a reactivation of a latent adenovirus infection, a nosocomial infection, a
community-acquired infection, or a donor-associated adenovirus infection.
This research has a number of limitations. Although a large number of adenovirus-positive
specimens were tested in this study, the specimens were collected for diagnostic purposes and,
thus, were likely to have been obtained from the most severely affected patients. In addition,
although 98% of the specimens were genotyped with good identity score agreements, relying
solely on the hypervariable regions of the hexon gene to distinguish strains may cause to be
missed other important genetic differences in strains that may correlate better with host
immunologic response and strain virulence. For instance, the fiber protein possesses cell
receptor binding sites, and alteration of these sites can alter the tissue tropism of an adenovirus
[56]. Similarly, genes coding for certain adenovirus early proteins may influence adenovirus
cell-to-cell transmission [57]. Thus, the hexon gene sequencing approach will merit further
study augmented with other molecular typing methods to reduce the risk of missing important
recombinations of adenovirus.
In conclusion, the hexon gene sequence typing strategy used in this study seems to be very
useful. Additional studies of such typing in concert with other molecular typing methods are
warranted. Molecular methods have the potential to assist clinicians in evaluating and treating
specific patients and in aiding public health officials in investigating adenovirus infection
epidemics. The suggestion that adenovirus types 3, 5, and 21 may be associated with more
frequent or more severe disease, as well as the unexpected lack of such associations with
adenovirus type 7, merit further molecular investigation to determine whether there are viral
predictors of disease severity. Finally, our findings that clinical adenovirus infection was often
associated with hospitalization and that, more often than expected, multiple adenovirus types
could be detected add to our new appreciation of the morbidity associated with adenovirus
infection.
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